Cargando…

Longitudinal changes in bone and mineral metabolism after cessation of cinacalcet in dialysis patients with secondary hyperparathyroidism

BACKGROUND: The calcimimetic agent cinacalcet is effective for the management of secondary hyperparathyroidism (SHPT) in dialysis patients. Changes to reimbursement of cinacalcet in Australia provided an opportunity to assess effects of medication cessation on biochemical and clinical outcomes in di...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ruderman, Irene, Smith, Edward R., Toussaint, Nigel D., Hewitson, Tim D., Holt, Stephen G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5952622/ https://www.ncbi.nlm.nih.gov/pubmed/29764395 http://dx.doi.org/10.1186/s12882-018-0910-9

Ejemplares similares

The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism
por: Bucharles, Sérgio Gardano Elias, et al.
Publicado: (2019)

Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis
por: Warady, Bradley A., et al.
Publicado: (2020)

Bone histomorphometry before and after long-term treatment with cinacalcet in dialysis patients with secondary hyperparathyroidism
por: Behets, Geert J, et al.
Publicado: (2015)

Changes in bone microarchitecture following parathyroidectomy in patients with secondary hyperparathyroidism
por: Ruderman, Irene, et al.
Publicado: (2021)

Effectiveness of Cinacalcet in Patients with Chronic Kidney Disease and Secondary Hyperparathyroidism Not Receiving Dialysis
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2016)

Bone microarchitecture in patients undergoing parathyroidectomy for management of secondary hyperparathyroidism
por: Ruderman, Irene, et al.
Publicado: (2020)

Cinacalcet adherence in dialysis patients with secondary hyperparathyroidism in Lombardy Region: clinical implications and costs
por: Roggeri, Alessandro, et al.
Publicado: (2020)

Long-term effectiveness of cinacalcet in non-dialysis patients with chronic kidney disease and secondary hyperparathyroidism
por: Pérez-Ricart, Ariadna, et al.
Publicado: (2019)

Pharmacogenetic analysis of cinacalcet response in secondary hyperparathyroidism patients
por: Jeong, Sohyun, et al.
Publicado: (2016)

Cinacalcet Treatment of Primary Hyperparathyroidism
por: Rothe, H. M., et al.
Publicado: (2011)

Successful treatment of inoperable recurrent secondary hyperparathyroidism with cinacalcet HCl
por: Eriguchi, Rieko, et al.
Publicado: (2008)

PTH-dependence of the effectiveness of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Akizawa, Tadao, et al.
Publicado: (2016)

Efficacy of Evocalcet in Previously Cinacalcet-Treated Secondary Hyperparathyroidism Patients
por: Koiwa, Fumihiko, et al.
Publicado: (2021)

Parathyroidectomy Versus Cinacalcet for the Treatment of Secondary Hyperparathyroidism in Hemodialysis Patients
por: Alvarado, Luis, et al.
Publicado: (2022)

Vascular calcification in skin and subcutaneous tissue in patients with chronic and end-stage kidney disease
por: Ruderman, Irene, et al.
Publicado: (2020)

Serum phosphorus reduction in dialysis patients treated with cinacalcet for secondary hyperparathyroidism results mainly from parathyroid hormone reduction
por: Zitt, Emanuel, et al.
Publicado: (2013)

Management of pre-renal transplant secondary hyperparathyroidism: parathyroidectomy versus cinacalcet
por: Elhadedy, Muhammed Ahmed, et al.
Publicado: (2023)

Comparison between Calcitriol and Calcitriol Plus Low-Dose Cinacalcet for the Treatment of Moderate to Severe Secondary Hyperparathyroidism in Chronic Dialysis Patients
por: Lee, Yueh-Ting, et al.
Publicado: (2013)

Treatment with cinacalcet increases plasma sclerostin concentration in hemodialysis patients with secondary hyperparathyroidism
por: Kuczera, Piotr, et al.
Publicado: (2016)

Role of Cinacalcet in Treating Cardiac Dysfunction Secondary to Hyperparathyroidism: A Case Series
por: Ohri, Alpana, et al.
Publicado: (2022)

Cinacalcet use in secondary hyperparathyroidism: a machine learning-based systematic review
por: Li, Xiaosong, et al.
Publicado: (2023)

Clinical Use of Cinacalcet in MEN1 Hyperparathyroidism
por: Moyes, V. J., et al.
Publicado: (2010)

Changes in Markers of Mineral Metabolism After Living Kidney Donation
por: Tan, Sven-Jean, et al.
Publicado: (2017)

Successful cinacalcet treatment of refractory secondary hyperparathyroidism due to multiple lung parathyroid adenomas
por: Sugi, Orie, et al.
Publicado: (2010)

Gallstones were associated with the gastrointestinal adverse events of cinacalcet in hemodialysis patients with secondary hyperparathyroidism
por: Otsuka, Keiichi, et al.
Publicado: (2018)

Paricalcitol vs. cinacalcet for secondary hyperparathyroidism in chronic kidney disease: A meta-analysis
por: Xu, Wei, et al.
Publicado: (2020)

Comparison of the Oral Calcimimetics Evocalcet and Cinacalcet in East Asian Patients on Hemodialysis with Secondary Hyperparathyroidism
por: Ni, Zhaohui, et al.
Publicado: (2023)

Parathyroid Apoplexy Following Cinacalcet Treatment in Primary Hyperparathyroidism
por: Di Dalmazi, Giulia, et al.
Publicado: (2018)

Cinacalcet and primary hyperparathyroidism: systematic review and meta regression
por: Ng, Cheng Han, et al.
Publicado: (2020)

Cognitive impairment reversed by cinacalcet administration in primary hyperparathyroidism
por: Timmons, J. G., et al.
Publicado: (2021)

Successful Early Treatment of Severe Neonatal Hyperparathyroidism With Cinacalcet
por: Thakkar, Keya, et al.
Publicado: (2021)

Effect of Sevelamer on Calciprotein Particles in Hemodialysis Patients: The Sevelamer Versus Calcium to Reduce Fetuin-A-Containing Calciprotein Particles in Dialysis (SCaRF) Randomized Controlled Trial
por: Smith, Edward R., et al.
Publicado: (2020)

A randomised controlled trial to examine the effects of cinacalcet on bone and cardiovascular parameters in haemodialysis patients with advanced secondary hyperparathyroidism
por: Eddington, Helen, et al.
Publicado: (2021)

Parathyroidectomy versus cinacalcet for tertiary hyperparathyroidism; a retrospective analysis
por: Dulfer, R. R., et al.
Publicado: (2019)

Reduced hip bone mineral density is associated with high levels of calciprotein particles in patients with Fabry disease
por: Bruell, S., et al.
Publicado: (2022)

Long-term treatment with cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism
por: Meola, Mario, et al.
Publicado: (2009)

Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism
por: Nakayama, Kazunori, et al.
Publicado: (2013)

Bridging adults and paediatrics with secondary hyperparathyroidism receiving haemodialysis: a pharmacokinetic‐pharmacodynamic analysis of cinacalcet
por: Chen, Ping, et al.
Publicado: (2019)

Effectiveness of cinacalcet treatment for secondary hyperparathyroidism on hospitalization: Results from the MBD-5D study
por: Asada, Shinji, et al.
Publicado: (2019)

Cost-effectiveness analysis of cinacalcet vs. paricalcitol in the treatment of hyperparathyroidism secondary to chronic kidney disease
por: Ponce, Daniela, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_c5qm77nnc34dud4j6np0532rt7